Locations:
Search
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Neoadjuvant immunotherapy improves outcomes
Real-world results reporting aims to make treatments safer and more effective
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Patients receive specialized inpatient and outpatient care for cellular, gene and immune cell-engaging therapies
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
Clinicians highlight the need to educate patients about warning signs
Combination therapy demonstrates effectiveness in first-line treatment setting
Research indicates strong rationale for expanding trial eligibility criteria
Dedicated investigators and clinicians bring expertise in drug development and flexible study design
Advertisement
Advertisement